journal article·2026-03

Transmucosal delivery of a dendritic cell-targeting intranasal nanovaccine boosts HIV-1 specific mucosal and systemic immune responses

Yaotian Chang, Xiaoqian Xin, Tongshuai Wang, Xiaopan Liu, Qingyu Wang, Yuhua Shi, Yaming Shan

Acta Biomaterialia· Volume 213
Publisher page

Abstract

The induction of secretory IgA (sIgA) on mucosal surfaces is crucial for developing vaccines that effectively prevent Human immunodeficiency virus type 1 (HIV-1) transmission. However, the mucosal barrier significantly limits antigen absorption, resulting in weak systemic and mucosal immune responses. In this study, a novel dual-function nanovaccine for intranasal administration of HIV-1 native-like envelope (Env) proteins was developed. Specifically, the amphiphilic polymer coating (DPPD2) was synthesized by conjugating P-D2, a peptide that targets the CD11c receptor on dendritic cells (DCs), to DSPE-PEG (DP). DPPD2 was then employed to surface-functionalize the amino-modified mesoporous silica nanoparticle (MSN) that was loaded with Env and Toll-like receptor 9 agonist CpG, resulting in a DC-targeting nanovaccine. DPPD2/Env/CpG@MSN could synergistically boost trans-mucosal penetration of Env proteins and the recruitment, antigen uptake and activation of submucosal DCs. More importantly, we found that DPPD2/Env/CpG@MSN promoted germinal center (GC) responses in the muco-associated lymphoid tissue and draining lymph nodes, further leading to significantly enhanced HIV-1-specific sIgA antibody levels in situ and distant mucosal sites. Furthermore, systemic immune responses such as serum neutralizing antibodies against heterologous HIV-1 pseudoviruses and systemic T cell immunity were improved. Our study introduces a unique functional intranasal nanovaccine, providing a basis for developing subunit vaccines against mucosal viral infections. STATEMENT OF SIGNIFICANCE: The development of effective strategies to prevent mucosal transmission of HIV-1 is crucial for combating AIDS. Current HIV-1 Env subunit vaccines have shown limited immunogenicity in mucosal immunity studies. This work developed an intranasal nanovaccine, DPPD2/Env/CpG@MSN, to synergistically enhance trans-mucosal penetration of the Env protein and its subsequent uptake by submucosal DCs. The results demonstrated that DPPD2/Env/CpG@MSN effectively boosted germinal center responses and antibody production. The levels of Env-specific sIgA antibodies were significantly elevated in both local and distant mucosal sites. Moreover, the nanovaccine also elicited robust Env-specific T cell immune responses in spleen. This design provides a promising strategy for enhancing the immunogenicity of HIV-1 subunit vaccines in mucosal vaccination.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: HIV Research and Treatment · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (60)

Show source-provided references
1. Surface-functionalized silica-coated calcium phosphate nanoparticles efficiently deliver DNA-based HIV-1 trimeric envelope vaccines against HIV-110.1021/acsami.1c16989 ↗
2. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies10.1038/s41577-022-00753-w ↗
3. HIV-1 env trimers asymmetrically engage CD4 receptors in membranes10.1038/s41586-023-06762-6 ↗
4. Antibodies in HIV-1 vaccine development and therapy10.1126/science.1241144 ↗
5. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques10.1084/jem.183.1.215 ↗
6. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection10.1126/science.280.5362.427 ↗
7. Mucosal immunity: induction, dissemination, and effector functions10.1111/j.1365-3083.2009.02319.x ↗
8. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity10.1126/scitranslmed.abn1413 ↗
9. Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings10.1016/j.hlife.2025.05.001 ↗
10. An HIV-1 vaccine based on bacterium-like particles elicits env-specific mucosal immune responses10.1016/j.imlet.2020.03.002 ↗
11. Vaccine with bacterium-like particles displaying HIV-1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques10.1111/1751-7915.14022 ↗
12. Mucosal vaccine adjuvants update
13. Biomaterial approaches for understanding and overcoming immunological barriers to effective oral vaccinations10.1002/adfm.201907170 ↗
14. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses10.1016/j.actbio.2017.10.019 ↗
15. Transmucosal delivery of nasal nanovaccines enhancing mucosal and systemic immunity10.1021/acs.nanolett.3c03419 ↗
16. Polydopamine coating enhances mucopenetration and cell uptake of nanoparticles10.1021/acsami.8b18107 ↗
17. Bilayer-functionalized mesoporous silica nanoparticles for overcoming multiple barriers of mucus clearance, intestinal epithelium and P-glycoprotein efflux10.1016/j.matdes.2024.112820 ↗
18. The Nano–Intestine interaction: understanding the location-oriented effects of engineered nanomaterials in the Intestine10.1002/smll.201907665 ↗
19. Competitive success10.1038/nri713 ↗
20. Dendritic cells and the control of immunity10.1038/32588 ↗
21. A comprehensive understanding of the gut mucosal immune system in allergic inflammation10.1016/j.alit.2018.09.004 ↗
22. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors10.1089/153685903321538026 ↗
23. VEGF therapy: risky business for established plaques?10.1182/blood-2006-10-050856 ↗
24. Specialized lectures (SL)10.1046/j.1432-1033.270.s1.6.x ↗
25. Microparticle surface modifications targeting dendritic cells for non-activating applications10.1016/j.biomaterials.2012.06.049 ↗
26. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis10.1182/blood-2003-08-2729 ↗
27. Structures and immune recognition of Env trimers from two Asia prevalent HIV-1 CRFs10.1038/s41467-023-40321-x ↗
28. HIV-1 vaccine design through minimizing envelope metastability10.1126/sciadv.aau6769 ↗
29. Periodic mesoporous organosilica as a nanoadjuvant for subunit vaccines elicits potent antigen-specific germinal center responses by activating naive B cells10.1021/acsnano.3c00991 ↗
30. Innate antiviral immune signaling, viral evasion and modulation by HIV-110.1016/j.jmb.2013.12.003 ↗
31. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles10.1038/ncomms12041 ↗
32. Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties10.1016/j.addr.2017.10.001 ↗
33. Lactoferrin-modified PLGA nanoparticles for pregabalin: development, characterization, in vitro targeting and pharmacodynamic evaluation10.1007/s13346-025-01848-2 ↗
34. Mucosal vaccines — Fortifying the frontiers10.1038/s41577-021-00583-2 ↗
35. Function of mucosa-associated lymphoid tissue in antibody formation10.3109/08820131003680369 ↗
36. Thymic function in MHC class II–deficient patients10.1016/j.jaci.2012.10.040 ↗
37. Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine10.1016/j.jconrel.2022.04.036 ↗
38. Mucosal vaccination for influenza protection enhanced by catalytic Immune-adjuvant10.1002/advs.202000771 ↗
39. CpG oligodeoxynucleotides facilitate delivery of whole inactivated H9N2 influenza virus via transepithelial dendrites of dendritic cells in Nasal Mucosa10.1128/JVI.00296-15 ↗
40. CCR7 acts as both a sensor and a sink for CCL19 to coordinate collective leukocyte migration10.1126/sciimmunol.adc9584 ↗
41. Alcaligenes lipid A functions as a superior mucosal adjuvant to monophosphoryl lipid A via the recruitment and activation of CD11b+ dendritic cells in nasal tissue10.1093/intimm/dxad045 ↗
42. The role of Th17 cytokines in primary mucosal immunity10.1016/j.cytogfr.2010.11.002 ↗
43. IL-17-dependent SIgA-mediated protection against nasal bordetella pertussis infection by live attenuated BPZE1 vaccine10.1038/s41385-018-0073-9 ↗
44. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa10.1038/mi.2009.100 ↗
45. Are anti-HIV IgAs good guys or bad guys?10.1186/s12977-014-0109-5 ↗
46. Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 Vector Prime, env protein boost immunizations in Rhesus monkeys
47. HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge10.1038/s41467-019-08739-4 ↗
48. Chiral Nanosilica drug delivery systems stereoselectively interacted with the intestinal mucosa to improve the oral adsorption of insoluble drugs10.1021/acsnano.2c10818 ↗
49. Nanodelivery strategies modulating tumor stromal cells for reverting the immunosuppressive tumor microenvironment10.1016/j.cclet.2025.112036 ↗
50. Nanoparticles exhibiting virus-mimic surface topology for enhanced oral delivery10.1038/s41467-023-43465-y ↗
51. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse10.1016/j.jconrel.2014.10.026 ↗
52. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability10.1016/j.immuni.2019.10.008 ↗
53. Germinal center B cell dynamics10.1016/j.immuni.2016.09.001 ↗
54. Periodic mesoporous organosilica-loaded mincle agonists enhance the immunogenicity of COVID-19 subunit vaccines by dual activation of B cells and dendritic cells10.1016/j.actbio.2024.12.056 ↗
55. T follicular helper cell heterogeneity: time, space, and function10.1111/imr.12740 ↗
56. Recent progress in mucosal vaccine development: potential and limitations10.1038/nri3251 ↗
57. Nasal vaccines for respiratory infections10.1038/s41586-025-08910-6 ↗
58. Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses10.1038/mi.2016.28 ↗
59. Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy10.1016/j.jconrel.2024.07.056 ↗
60. NK cell membrane/MnO2 hybrid nanoparticle-adjuvanted intranasal vaccines synergistically boost protective immunity against H1N1 influenza infection10.1016/j.cej.2024.157381 ↗